Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company focused on discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The company describes itself as dedicated to applying a precision neuroscience approach, using its receptor associated protein (RAP) technology platform to generate product candidates that aim to address limitations of conventional neurology drug discovery.

According to Rapport, its founders made pioneering discoveries related to the function of receptor associated proteins in the brain. These discoveries form the scientific basis of the RAP technology platform, which is designed to map and target specific neuronal receptor complexes. By focusing on RAPs that are expressed only in discrete brain regions, the platform supports the design of drug candidates intended to achieve neuroanatomical specificity.

Core pipeline and RAP-219

Rapport’s precision neuroscience pipeline is anchored by its lead investigational drug, RAP-219. The company characterizes RAP-219 as a potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM). While AMPARs are distributed widely in the central nervous system, Rapport reports that the receptor associated protein TARPγ8 is expressed only in discrete brain regions, including the hippocampus and neocortex, where focal seizures often originate, and has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events.

Based on this biology, Rapport states that RAP-219 is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed in discrete regions of the brain. The company believes this precision approach has the potential to provide a differentiated profile compared with traditional neuroscience medications and has described RAP-219 as having “pipeline-in-a-product” potential due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8.

Therapeutic focus areas

Rapport’s disclosures describe a pipeline that includes epilepsy and psychiatric and pain indications. The company is pursuing RAP-219 as a potential treatment for:

• Drug-resistant focal onset seizures (FOS)
• Bipolar mania
• Diabetic peripheral neuropathic pain (DPNP)

Rapport has reported positive topline results from a Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures, including statistically significant reductions in long episodes (an electrographic biomarker) and clinical seizures over an 8-week treatment period, with RAP-219 generally well tolerated in that study population. The company has also described additional analyses of this trial, including early onset of action, consistency of median response over the treatment period, and improvements in seizure severity measures among certain patients.

In addition to epilepsy, Rapport is conducting a Phase 2 trial of RAP-219 in bipolar mania. The company has also discussed plans and regulatory interactions related to a Phase 2 program in diabetic peripheral neuropathic pain. Across these indications, Rapport positions RAP-219 as a precision small molecule candidate being evaluated in neurological and psychiatric settings where AMPA receptor biology and TARPγ8 expression are considered relevant.

Broader discovery and preclinical programs

Beyond RAP-219, Rapport reports that it is advancing additional discovery and preclinical programs leveraging its RAP technology platform. The company has highlighted work in:

• Chronic pain and migraine, including an agonist of the α6β4 nicotinic acetylcholine receptor (nAChR) as a potential non-opioid, non-central nervous system approach for chronic pain and migraine
• Hearing and vestibular disorders

Rapport has stated that it has initiated investigational new drug (IND)-enabling activities for its α6β4 nAChR development candidate. It has also described this target as clinically validated and part of its strategy in pain indications.

Formulation and adherence initiatives

The company is also working on a long-acting injectable (LAI) formulation of RAP-219. Rapport notes that nonadherence to prescribed antiseizure medications is common and can lead to breakthrough seizures. In its communications, the company has stated that a long-acting injectable formulation of RAP-219 is being developed with the goal of improving adherence and expanding the potential clinical utility of RAP-219 across its indications. The company has described ongoing IND-enabling activities to support a Phase 1 clinical study of a long-acting injectable formulation in healthy volunteers.

Regulatory and clinical development

Rapport has reported multiple interactions with the U.S. Food and Drug Administration (FDA) related to its programs. For RAP-219 in focal onset seizures, the company has disclosed an end-of-Phase 2 meeting with the FDA and plans to advance into registrational Phase 3 trials. It has also reported the initiation of an open-label, long-term safety trial allowing participants from the Phase 2a FOS trial to resume RAP-219 treatment.

In diabetic peripheral neuropathic pain, Rapport has noted that the FDA removed a clinical hold on the RAP-219 IND after further discussions, although the company has indicated that it is deferring further investment in that particular RAP-219 DPNP program while it prioritizes its α6β4 chronic pain and migraine program. These disclosures illustrate how regulatory feedback and internal prioritization shape the company’s development plans.

Public company status and listing

Rapport Therapeutics, Inc. is a public company with its common stock registered under Section 12(b) of the Securities Exchange Act of 1934. According to its SEC filings, the company’s common stock, with a par value of $0.001 per share, trades on The Nasdaq Global Market under the symbol RAPP. The company has used public offerings of common stock under an effective shelf registration statement on Form S-3 to raise capital for its clinical and research activities and has also disclosed the termination of a prior at-the-market sales agreement prospectus.

In its filings and press releases, Rapport has described itself as a clinical-stage biotechnology company with operations associated with Boston, Massachusetts, and has referenced participation in healthcare and investor conferences in locations such as San Francisco, New York City, London, and virtual industry events.

Business model and focus

Based on its public statements, Rapport’s business model centers on the research, clinical development, and potential future commercialization of small molecule precision medicines derived from its RAP technology platform. The company emphasizes:

• Targeting receptor associated proteins that regulate neuronal receptor expression and function
• Designing compounds that seek to achieve neuroanatomical specificity by focusing on RAPs expressed in discrete brain regions
• Building a pipeline in neurological and psychiatric disorders, with epilepsy as a central area of focus
• Expanding into pain and sensory indications, including chronic pain, migraine, and hearing or vestibular disorders

Rapport’s disclosures also highlight its use of clinical biomarkers, such as long episodes recorded by implanted neurostimulation systems, to evaluate treatment effects in focal onset seizures. The company has presented data at scientific meetings, including the American Epilepsy Society Annual Meeting, to share trial results and post hoc analyses with the medical and scientific community.

Risk and forward-looking statements

As a clinical-stage biotechnology company, Rapport notes in its forward-looking statements that its programs are subject to risks and uncertainties typical for drug development. These include risks related to research and development activities, regulatory approvals, dependence on third parties for clinical trials and manufacturing, financial needs, intellectual property, and the competitive landscape. The company’s public communications repeatedly reference these factors and direct readers to the “Risk Factors” sections of its periodic reports filed with the U.S. Securities and Exchange Commission for more detail.